Crossmark

Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial

Crossref DOI link: https://doi.org/10.1038/s41392-024-01957-3

Published Online: 2024-09-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Han, Xiao

Guo, Jun

Li, Lingyu

Huang, Yong

Meng, Xue https://orcid.org/0000-0001-6311-2649
Wang, Linlin

Zhu, Hui

Meng, Xiangjiao

Shao, Qian

Li, Xing

Zhang, Yan

Wang, Jin

Chen, Yanhua

Zhang, Yingjie

Chen, Yiru

Zhu, Changbin

Wang, Zhehai
Funding

Funding for this research was provided by:

Natural Science Foundation of Shandong Province (ZR2023LSW024)

Shandong medical and health science and technology development plan project
License Information

Text and Data Mining valid from 2024-09-16

Version of Record valid from 2024-09-16
More Information

Article History

Received: 27 March 2024

Revised: 12 August 2024

Accepted: 27 August 2024

First Online: 16 September 2024

Competing interests

: X.L., J.W., Y.C., and C.Z. are employed by Amoy Diagnostics. The other authors declare no competing interests.

Document is current

Any future updates will be listed below